Serological Screening of TORCH Agents as an Etiology of Spontaneous Abortion in Dhulikhel Hospital, Nepal
American Journal of Biomedical and Life Sciences
Volume 2, Issue 2, April 2014, Pages: 34-39
Received: Mar. 2, 2014; Accepted: Apr. 8, 2014; Published: Apr. 10, 2014
Views 3965      Downloads 252
Authors
Dhruba Acharya, Department of Microbiology, Kathmandu University School of Medical Sciences, Kavre, P.O.Box- 11008, Nepal
Abha Shrestha, Department of Obstetrics and Gynecology, Kathmandu University School of Medical Sciences, Kavre, Nepal
Bikash Bogati, Department of Microbiology, Dhulikhel Hospital-Kathmandu University Hospital, Kavre, Nepal
Kishor Khanal, Department of Community Medicine, Kathmandu University School of Medical Sciences, Kavre, Nepal
Shrinkhala Shrestha, Department of Community Programs, Dhulikhel Hospital- Kathmandu University Hospital, Kavre, Nepal
Prabin Gyawali, Department of Biochemistry, Kathmandu University School of Medical Sciences, Kavre, Nepal
Article Tools
Follow on us
Abstract
The role of TORCH infections as a cause of spontaneous abortions is still debatable with conflicting results where geographical variation may play a significant role. This study was undertaken to discover the association of TORCH infections in women with spontaneous abortions by serological testing. The descriptive case control study was conducted from January to December, 2012. A serological evaluation was carried out to determine the presence of Toxoplasma gondii, Rubella, Cytomegalovirus (CMV) and Herpes Simplex Virus (HSV) specific immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies, using commercial diagnostic kits by enzyme-linked immunosorbent assay (ELISA) technique. Mean age of the study and control subjects were 24.8+/-6.4 and 23.8+/-3.8 years respectively where 72.8% of the study subjects were of the age between 20 to 35 years and 23% of the women with spontaneous abortion were below 20 years. Most of the cases were of incomplete abortions (43%) followed by complete abortions (26%). Only 1.3% of both IgG and IgM seropositivity against TORCH agents were noted among the study subjects whereas highest IgG seropositivity was detected with Rubella (86.8%) followed by HSV-I (72.8%). An infection susceptibility rate of 77.9% to Toxoplasma gondii, 11.7% to Rubella, 51.9% to CMV, 36.4% to HSV-I and 84.4% to HSV-II was noted. No significant difference in relation to age and type of abortion was found in seropositivity between the study and the control subjects. This study, probably the first of its kind from Nepal, suggests that current infection with TORCH agents might not be the possible etiology of spontaneous abortion. Serological TORCH screening may not be conclusive.
Keywords
Screening, TORCH Agents, Spontaneous Abortion, Immunoglobulin, Seropositivity
To cite this article
Dhruba Acharya, Abha Shrestha, Bikash Bogati, Kishor Khanal, Shrinkhala Shrestha, Prabin Gyawali, Serological Screening of TORCH Agents as an Etiology of Spontaneous Abortion in Dhulikhel Hospital, Nepal, American Journal of Biomedical and Life Sciences. Vol. 2, No. 2, 2014, pp. 34-39. doi: 10.11648/j.ajbls.20140202.11
References
[1]
J.D. Pizzo, “Congenital infections (TORCH)”, Pediatrics in Review 2011, vol. 32(12), pp. 537-542.
[2]
V. Kumar,A.K. Abbas, N. Fausto, J. Aster, Robbins & Cotran, Pathologic Basis of Disease, Elsevier, 8th ed., 2009.
[3]
Y. Maruyama, H. Sameshima, M. Kamitomo, et al., “Fetal manifestations and poor outcomes of congenital cytomegalovirus infections: possible candidates for intrauterine antiviral treatments,” J Obstet Gynecol, vol. 33, pp. 619-623, 2007.
[4]
Z. Li, C. Yan, P. Liu, R. Yan, Z. Feng, “The prevalence of the serum anti-bodies to TORCH among women before pregnancy or in the early period of pregnancy in Beijing,” International Journal of Clinical Chemistry and Diagnostic Laboratory Medicine, vol. 403, pp. 212-215, 2009.
[5]
D. Turbadkar, M Mathur, M. Rele. “Seroprevalence of torch infection in bad obstetric history,” Indian Journal of Medical Microbiology, vol.21, pp. 108-110, 2003.
[6]
M.E. Paul, “Disorders of reproduction,” Primary Care, vol. 21, pp. 367-386, 1994.
[7]
P.R. Summers, “Microbiology relevant to recurrent miscarriage,” Indian Journal of Medical Residents, vol. 100, pp. 19-22, 1994.
[8]
B.J. Stegmann, J.C. Carey, “TORCH infections. Toxoplasmosis, Other (syphilis, varicella-zoster, parvovirus B19), Rubella, Cytomegalovirus (CMV), and Herpes infections,” Current Women’s Health Report, vol. 2, pp. 253-258, 2002.
[9]
C.P. Griebel, J. Halvorsen, T.B. Golemon, A.A. Day “Management of spontaneous abortion,” American Family Physician, vol. 72, pp. 1243-1250, 2005.
[10]
G.M. Stirrat, “Recurrent miscarriage II: clinical associations, causes, and management,” The Lancet, vol. 336, pp. 728-733,1990.
[11]
M.L. Li, C. Hui, T.J. Ping, et al. “Evaluation of etiological characteristics of Chinese women with recurrent spontaneous abortion: a single center study,” Chinese Medical Journal, vol. 124, pp. 1310-1315, 2011.
[12]
N. Kumari, N. Morris, R. Dutta, “Is screening of TORCH worthwhile in women with bad obstetric history: an observation from Eastern Nepal,” Journal of Health Population and Nutrition, vol. 29, pp. 77-80, 2011.
[13]
S. Lamichhane, S. Malla, S. Basnyat, et al. “Seroprevalence of IgM antibodies against the agents of TORCH infection among the patients visiting National Public Health Laboratory, Teku, Kathmandu,” Journal of Nepal Health Research Council, vol. 2, pp. 1-25, 2007.
[14]
N. Thapliyal, P.K. Shukla, B. Kumar, S. Upadhyay, G. Jain, “TORCH infection in women with bad obstetric history—a pilot study in Kumaon region,” Indian Journal of Pathology and Microbiology, vol. 48, pp. 551-553, 2005.
[15]
E. Jauniaux, R.G. Farquharson, O.B. Christiansen, “Evidence based guidelines for the investigation and medical treatment of recurrent miscarriage,” Human Reproduction, vol. 21, pp. 2216-2222, 2006.
[16]
A. Cullen, S. Brown, M. Cafferkey, N. O’Brien, E. Griffin, “Current use of TORCH screen in the diagnosis of congenital infection,” Journal of Infection, vol. 36, pp. 185-188, 1998.
[17]
B.D. Navolan, I.M. Ciohat, A.E. Tigla, D. Vasies, V. Dumitrascu, “ Risk assessment for TORCH complex infection agents during pregnancy-preliminary study,” Timisoara Medical Journal, vol. 22, pp. 15-19, 2012.
[18]
A.M. Alsamarai, Z. Khalil, M. Aljumaili, “Seroepidemiology of Toxoplasma, Rubella, Cytomegalovirus and Herpes Simplex Virus -2 in women with bad obstetric history. PART I: Toxoplasma and Rubella infections,” Our Dermatology Online, vol. 4, pp. 522-535, 2013.
[19]
G.O. Ajayi, S.A. Omilabu, “Prenatal diagnoses of cytomegalovirus (CMV), rubella, toxoplasmosis, varicella, parvovirus, herpes simplex and syphilis. The Lagos programme experience,” Clinical and Experimental Obstetrics and Gynecology, vol. 37, pp. 37-38, 2010.
[20]
C. A. Jones, “Vertical transmission of genital herpes: prevention and treatment options,” Drugs, vol. 69, pp. 421-434, 2009.
[21]
D. Leland, M.L. French, M.B. Kleiman, R.L. Schreiner, “The use of TORCH titers,” Pediatrics, vol 72, pp. 41-43, 1983.
[22]
S.K. Rai, H. Shibata, K. Sumi, “Toxoplasma antibody prevalence in Nepalese pregnant women with bad obstetric history,” Southeast Asian Jorunal of Tropical Medicine and Public Health, vol. 29, pp. 739-743, 1998.
[23]
D. Acharya, S. Shrestha, B. Bogati, “Immune status in infection by cytomegalovirus in women with bad obstetric history,” International Journal of Infection and Microbiology, vol. 2, pp. 3-6, 2013.
[24]
T. Kubo, S.K. Rai, M. Nakanishi, T. Yamano, “Seroepidemiological study of herpes viruses in Nepal,” Southeast Asian Journal of Tropical Medicine and Public Health, vol 22, pp.323-325, 1991.
[25]
R.N. Kaur, D. Gupta, M.K. Nair, M.D. Mathur, “Screening for TORCH infections in pregnant women: a report from Delhi,” Southeast Asian Journal of Tropical Medicine and Public Health, vol. 30, pp. 284-286, 1999.
[26]
G.M. Bhopale, “Review, pathogenesis of Toxoplasma,” Comparative Immunology, Microbiology and Infectious Diseases, vol. 26, pp. 213-222, 2003.
[27]
J. Kishor, R. Mishra, A. Paisal, Y. Pradeep, “Adverse reproductive outcome induced by Parvovirus B19 and TORCH infections in women with high-risk pregnancy,” Journal of Infections in Developing Countries, vol. 5, pp. 868-873, 2011.
[28]
A.H. Razzak, S.A. Wais, A.Y. Sayid, “Toxoplasmosis: the innocent suspect of pregnancy wastage in Iraq,” Eastern Mediterranean Health Journal, vol. 11, pp. 525-632, 2005.
[29]
A. Garcia-Enguidanos, M.E. Calle, J. Valero, S. Luna, V. Dominguez-Rojas, “Risk factors in miscarriage: a review,” European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 102, pp. 111-119, 2002.
[30]
S.A. Abdel-Fattah, A. Bhat, S. Illanes, J.L. Bartha, D. Carrington, “TORCH test for fetal medicine indications: only CMV is necessary in the United Kingdom,” Prenatal Diagnosis, vol. 25, pp. 1028-1031, 2005.
[31]
S.M. Garland, G.L. Gilbert, “Investigation of congenital infection- the TORCH screen is not a legitimate test,” Medical Journal of Australia, vol. 159, pp. 346-348, 1993.
[32]
N.A. Khan, S.N. Kazzi, “Yield and costs of screening growth retarded infants for TORCH infections,” American Journal of Perinatology, vol. 17, pp. 131-135, 2000.
[33]
K. Hedman, M. Lappalainen, I. Seppaia, O. Makela, “Recent primary toxoplasma infection indicated by a low avidity of specific IgG,” Journal of Infectious Diseases, vol. 159, pp. 736-740, 1989.
[34]
W.E. Owen, T.B. Martins, C.M. Litwins, W.L. Roberts, “Performance characteristics of six IMMUNITE 2000 TORCH assays,” American Journal of Clinical Pathology, vol. 126, pp. 900-905, 2006.
[35]
O. Liesenfield, J.G. Montaya, N.J. Tathineni, “Confirmatory serologic testing for acute toxoplasmosis and rate of induced abortions among women reported to have positive Toxoplasma IgM antibody titer,” American Journal of Obstetrics and Gynecology, vol. 184, pp. 140-145, 2001.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186